key: cord-0989690-5lnh4lfr authors: Sivalingam, Thivya; Inusa, Baba; Doyle, Pat; Oteng‐Ntim, Eugene title: COVID‐19 and the pulmonary complications of sickle cell disease date: 2020-10-08 journal: EJHaem DOI: 10.1002/jha2.105 sha: 663c31cbdcd82ce3227fcc0a080f1097db9f7160 doc_id: 989690 cord_uid: 5lnh4lfr Sickle cell disease (SCD) patients are commonly affected by pulmonary complications such as acute chest syndrome (ACS), pulmonary embolism (PE) and pneumonia that contribute to significant mortality risks. With a greater susceptibility to infection, they are deemed to be vulnerable patients during the current COVID‐19 pandemic. In emerging small case studies of SCD patients with COVID‐19 and further complicated by pneumonia, ACS, and/or PE, the clinical benefits of early exchange transfusion and Tocilizumab are evident. However, further clinical trials and larger cohort studies are essential to evaluate effective diagnostic and management options for this high‐risk group. It is significant to address the impact of the current COVID-19 pandemic on sickle cell disease (SCD) patients who are particularly vulnerable. This novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain causes pneumonia of variable severity, with severe illness in approximately 15-20% of infected patients. The main clinical presentations can include a persistent dry cough, fever (≥37.3 • C) and dyspnea [1] . However, in many cases no signs or symptoms are present, rendering the situation more challenging to control, particularly as a droplet infection. The United Kingdom has reported the most deaths in Europe with a higher risk of mortality in those of Black, Asian, and Minority Ethnic (BAME) groups. In particular, Black Afro-Caribbean individuals had a 1.9-fold increased risk in mortality compared to Caucasians [2] . Similar statistics were also observed in many South Asian ethnic groups. SCD patients are predominantly of BAME background and are more susceptible to infections due to manifestations such as functional asplenia and impaired complement activation [3] . Therefore, this This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2020 The Authors. An emerging number of case studies have suggested important associations between ACS and COVID-19. ACS is a leading cause of intensive care admissions and mortality in SCD patients [5] . It is a complex eJHaem. 2020;1:545-547. wileyonlinelibrary.com/journal/jha2 545 pulmonary condition often triggered by an atypical bacteria or less commonly by a virus. ACS and pneumonia can commonly be misdiagnosed due to comparable clinical presentations such as a fever, cough, dyspnea, and chest pain. Consequently, a delay in appropriate management due to challenges in the true diagnosis may lead to worsening of the patient's condition. Further to mimicking the symptoms, evidence suggest that SARS-COV-2 infection may also provoke a severe clinical course of ACS [6, 7] . Beerkens et al reported the case of a 21-year old patient with the HbSβ 0 -thalassemia SCD subtype who had developed ACS as a result of COVID-19 [6] . It emphasizes the need for much vigilance even in younger adults, particularly immunocompromised individuals. Moreover, patients from two case studies had been admitted primarily for a vaso-occlusive crisis (VOC) characterized by minor to severe pain with no initial presentations of flu-like symptoms [6, 7] . The suspicion of a [5] . On the contrary, positive cases of COVID-19 may not always display its signs on a chest X-ray, as highlighted in Patient 2 in the case study by Nur et al [7] . Therefore, using a more sensitive imaging method such as chest CT scans can help identify COVID-19 signs missed on chest X-rays. There is an obvious risk to sickle cell patients during this pandemic, To exemplify, Odièvre et al reported on the significant improvement in the severe respiratory status of a 16-year-old SCD patient (HbSS genotype), who developed ACS after the COVID-19 infection and was further complicated by bilateral pulmonary embolism [10] . Four days after initiating one pulse of intravenous TCZ, she required no additional respiratory support and thereafter discharged from the intensive care unit. IL-6 can be found at particularly elevated levels in the normal state of SCD patients but is further increased during VOC [11] . SARS-COV-2 proteins have also demonstrated to induce the upregulation of proinflammatory cytokines including IL-6 [12] . Such small case studies high- On the contrary, a cohort study of 83 SCD inpatients with COVID-19 at a French center suggested that neither transfusions nor hydroxyurea treatment were significant in preventing ICU admissions in a small subgroup [14] . The study results also inferred that SCD patients, typically a young population, may be at reduced risks of morbidity and mortality as increased disease severity is more commonly seen in those older than 45 years. In fact, a recent large observational study of 725 COVID-19 positive patients highlighted that only nine of 725 had SCD. Moreover, in comparison to their aged match controls the SCD group required a significantly lower number of ICU admissions and had no mortalities, despite their immunocompromised state [15] . This raises the question whether SCD (HbSS) may have protective effects against a severe COVID-19 infection, and if so, whether they are due to better healthcare surveillance of SCD patients or due to factors at a molecular level. Such conflicting evidence will require investigations at a larger scale to establish a more significant conclusion regarding the mortality Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19) related deaths by ethnic group, England and Wales -Office for National Statistics Infection in sickle cell disease: a review Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19) Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease Dramatic improvement after tocilizumab of severe COVID -19 in a child with sickle cell disease and acute chest syndrome Serum interleukin-6 levels in the steady state of sickle cell disease Why tocilizumab could be an effective treatment for severe COVID-19? Management of sickle cell disease Prognosis of patients with sickle cell disease and COVID-19: a French experience How to cite this article: Sivalingam T, Inusa B, Doyle P, Oteng-Ntim E. COVID-19 and the pulmonary complications of sickle cell disease The authors declare no conflict of interest.